Atrium Health Levine Cancer | Strategic Alliance Partners

November 19, 2020

Saad Z. Usmani, MD, FACP, discusses the significance of the FDA approval of daratumumab, carfilzomib, and dexamethasone in patients with relapsed/refractory multiple myeloma who have received at least 1 previous line of therapy.

October 22, 2020

In our exclusive interview, Saad Z. Usmani, MD, FACP, discusses the FDA approval of daratumumab, carfilzomib, and dexamethasone in relapsed/refractory multiple myeloma.

September 28, 2020

In our exclusive interview, Antoinette R. Tan, MD, of Atrium Health, discusses the FDA approval of the fixed-dose combination of pertuzumab and trastuzumab in HER2-positive breast cancer and highlights the results of the pivotal FeDeriCa trial.

September 10, 2020

Nilanjan Ghosh, MD, PhD, discusses remaining questions with BTK inhibitors in chronic lymphocytic leukemia and small lymphocytic lymphoma.

August 03, 2020

Saad ​Z. Usmani, MD, FACP, discusses the key takeaways from the randomized phase 2 SWOG 1211 trial in patients with newly diagnosed, high-risk multiple myeloma.

June 23, 2020

R. Wendel Naumann, MD, discusses the early results reported with STRO-002, the hope for this agent in the ovarian cancer space, and the next steps for this research.

May 20, 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

May 19, 2020

Peter Voorhees, MD, discusses the benefit of monoclonal antibodies in multiple myeloma.

May 04, 2020

R. Wendel Naumann, MD, discusses the FDA approval of niraparib in ovarian cancer and the impact on the current treatment paradigm.

May 02, 2020

Peter Voorhees, MD, discusses the evolution of idecabtagene vicleucel (ide-cel; bb2121) in the phase 2 KarMMa study in relapsed/refractory multiple myeloma.

May 02, 2020

R. Wendel Naumann, MD, gynecologic oncologist, Levine Cancer Institute, Carolinas HealthCare System/Atrium Health, discusses data with STRO-002 in patients with platinum-resistant/refractory ovarian cancer.

April 02, 2020

Jubilee Brown, MD, discusses germline and somatic testing in ovarian cancer.

March 20, 2020

Forrest Thompson, MD, discusses sequencing strategies in HER2-positive breast cancer.

February 14, 2020

The foremost choice in the treatment of patients with newly diagnosed multiple myeloma is determining whether a patient is eligible for transplant, as that choice will set the stage for all future decisions.

February 14, 2020

Saad Z. Usmani, MD, FACP, discusses the need for immediate treatment intervention in patients with relapsed/refractory multiple myeloma.

February 14, 2020

Saad Z. Usmani, MD, expands on some of the key principles to inform the treatment of patients with relapsed/refractory multiple myeloma.

February 12, 2020

Barry Paul, MD, discusses some of the newer data to emerge regarding relapsed/refractory multiple myeloma.

February 12, 2020

Barry A. Paul, MD, discusses the role of carfilzomib in the treatment of patients with relapsed/refractory multiple myeloma.

February 11, 2020

Shebli Atrash, MD, discusses investigational combinations with venetoclax (Venclexta) in relapsed/refractory multiple myeloma.

February 10, 2020

Shebli Atrash, MD, discusses some of the latest intriguing research in relapsed/refractory multiple myeloma.